Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D A Cameron

Showing results (111-120 of 128) with videos related to

Pageof 13
Sort By:
Clinical Endocrinology|April 1, 1990
The loss of circadian rhythm for intact parathyroid hormone and nephrogenous cyclic AMP in patients with primary hyperparathyroidismF C Logue, W D Fraser, S J Gallacher, et al.
Calcified Tissue International|September 18, 2007
The use of bone markers in a 6-week study to assess the efficacy of oral clodronate in patients with metastatic bone diseaseJ E Brown, E V McCloskey, J A Dewar, et al.
European Journal of Cancer (Oxford, England : 1990)|June 6, 2006
EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumoursM S Aapro, D A Cameron, R Pettengell, et al.
Breast Cancer Research and Treatment|February 13, 2017
The BIG 2.04 MRC/EORTC SUPREMO Trial: pathology quality assurance of a large phase 3 randomised international clinical trial of postmastectomy radiotherapy in intermediate-risk breast cancerJ S Thomas, A M Hanby, N Russell, et al.
European Journal of Cancer (Oxford, England : 1990)|November 25, 2010
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumoursM S Aapro, J Bohlius, D A Cameron, et al.
British Journal of Cancer|November 28, 2002
Block sequential adriamycin CMF--optimal non-myeloablative chemotherapy for high risk adjuvant breast cancer?D A Cameron, A Anderson, E Toy, et al.
British Journal of Cancer|December 1, 1996
High-dose chemotherapy supported by peripheral blood progenitor cells in poor prognosis metastatic breast cancer--phase I/II study. Edinburgh Breast GroupD A Cameron, J Craig, H Gabra, et al.
Neuron|November 16, 2001
A visual pigment expressed in both rod and cone photoreceptorsJ Ma, S Znoiko, K L Othersen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 3, 2012
Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozoleP E Goss, J N Ingle, S Martino, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 13, 2014
Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trialH Bonnefoi, S Litière, M Piccart, et al.
Pageof 13

Showing results (111-120 of 128) with videos related to

Sort By:
Pageof 13
Clinical Endocrinology|April 1, 1990
The loss of circadian rhythm for intact parathyroid hormone and nephrogenous cyclic AMP in patients with primary hyperparathyroidismF C Logue, W D Fraser, S J Gallacher, et al.
Calcified Tissue International|September 18, 2007
The use of bone markers in a 6-week study to assess the efficacy of oral clodronate in patients with metastatic bone diseaseJ E Brown, E V McCloskey, J A Dewar, et al.
European Journal of Cancer (Oxford, England : 1990)|June 6, 2006
EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumoursM S Aapro, D A Cameron, R Pettengell, et al.
Breast Cancer Research and Treatment|February 13, 2017
The BIG 2.04 MRC/EORTC SUPREMO Trial: pathology quality assurance of a large phase 3 randomised international clinical trial of postmastectomy radiotherapy in intermediate-risk breast cancerJ S Thomas, A M Hanby, N Russell, et al.
European Journal of Cancer (Oxford, England : 1990)|November 25, 2010
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumoursM S Aapro, J Bohlius, D A Cameron, et al.
British Journal of Cancer|November 28, 2002
Block sequential adriamycin CMF--optimal non-myeloablative chemotherapy for high risk adjuvant breast cancer?D A Cameron, A Anderson, E Toy, et al.
British Journal of Cancer|December 1, 1996
High-dose chemotherapy supported by peripheral blood progenitor cells in poor prognosis metastatic breast cancer--phase I/II study. Edinburgh Breast GroupD A Cameron, J Craig, H Gabra, et al.
Neuron|November 16, 2001
A visual pigment expressed in both rod and cone photoreceptorsJ Ma, S Znoiko, K L Othersen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 3, 2012
Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozoleP E Goss, J N Ingle, S Martino, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 13, 2014
Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trialH Bonnefoi, S Litière, M Piccart, et al.
Pageof 13